Literature DB >> 22710712

Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells.

F Calhabeu1, S Hayashi, J E Morgan, F Relaix, P S Zammit.   

Abstract

Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarcoma in childhood and is characterized by expression of myogenic proteins, including the transcription factors MyoD and myogenin. There are two main subgroups, embryonal RMS and alveolar RMS (ARMS). Most ARMS are associated with chromosomal translocations that have breakpoints in introns of either PAX3 or PAX7, and FOXO1A. These translocations create chimeric transcription factors termed PAX3/FOXO1A and PAX7/FOXO1A respectively. Upon ectopic PAX3/FOXO1A expression, together with other genetic manipulation in mice, both differentiating myoblasts and satellite cells (the resident stem cells of postnatal muscle) can give rise to tumours with ARMS characteristics. As PAX3 and PAX7 are part of transcriptional networks that regulate muscle stem cell function in utero and during early postnatal life, PAX3/FOXO1A and PAX7/FOXO1A may subvert normal PAX3 and PAX7 functions. Here we examined how PAX3/FOXO1A and PAX7/FOXO1A affect myogenesis in satellite cells. PAX3/FOXO1A or PAX7/FOXO1A inhibited myogenin expression and prevented terminal differentiation in murine satellite cells: the same effect as dominant-negative (DN) Pax3 or Pax7 constructs. The transcription of MyoD-target genes myogenin and muscle creatine kinase were suppressed by PAX3/FOXO1A or PAX7/FOXO1A in C2C12 myogenic cells again as seen with Pax3/7DN. PAX3/FOXO1A or PAX7/FOXO1A did not inhibit the transcriptional activity of MyoD by perturbing MyoD expression, localization, phosphorylation or interaction with E-proteins. Chromatin immunoprecipitation on the myogenin promoter showed that PAX3/FOXO1A or PAX7/FOXO1A did not prevent MyoD from binding. However, PAX3/FOXO1A or PAX7/FOXO1A reduced occupation of the myogenin promoter by RNA polymerase II and decreased acetylation of histone H4, but did not directly bind to the myogenin promoter. Together, these observations reveal that PAX3/FOXO1A and PAX7/FOXO1A act to prevent myogenic differentiation via suppression of the transcriptional activation of MyoD-target genes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710712     DOI: 10.1038/onc.2012.73

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

Review 1.  Tissue-resident mesenchymal stem/progenitor cells in skeletal muscle: collaborators or saboteurs?

Authors:  Robert N Judson; Regan-Heng Zhang; Fabio M A Rossi
Journal:  FEBS J       Date:  2013-06-24       Impact factor: 5.542

2.  A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.

Authors:  Shinji Kohsaka; Neerav Shukla; Nabahet Ameur; Tatsuo Ito; Charlotte K Y Ng; Lu Wang; Diana Lim; Angela Marchetti; Agnes Viale; Mono Pirun; Nicholas D Socci; Li-Xuan Qin; Raf Sciot; Julia Bridge; Samuel Singer; Paul Meyers; Leonard H Wexler; Frederic G Barr; Snjezana Dogan; Jonathan A Fletcher; Jorge S Reis-Filho; Marc Ladanyi
Journal:  Nat Genet       Date:  2014-05-04       Impact factor: 38.330

3.  Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma.

Authors:  Zhongqiu Xie; Mihaela Babiceanu; Shailesh Kumar; Yuemeng Jia; Fujun Qin; Frederic G Barr; Hui Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

4.  Sphingosine phosphate lyase regulates myogenic differentiation via S1P receptor-mediated effects on myogenic microRNA expression.

Authors:  Anabel S de la Garza-Rodea; Dianna M Baldwin; Babak Oskouian; Robert F Place; Padmavathi Bandhuvula; Ashok Kumar; Julie D Saba
Journal:  FASEB J       Date:  2013-10-24       Impact factor: 5.191

Review 5.  Mechanisms of impaired differentiation in rhabdomyosarcoma.

Authors:  Charles Keller; Denis C Guttridge
Journal:  FEBS J       Date:  2013-07-31       Impact factor: 5.542

6.  PAX3 Confers Functional Heterogeneity in Skeletal Muscle Stem Cell Responses to Environmental Stress.

Authors:  Audrey Der Vartanian; Marie Quétin; Stéphanie Michineau; Frédéric Auradé; Shinichiro Hayashi; Christelle Dubois; Didier Rocancourt; Bernadette Drayton-Libotte; Anikó Szegedi; Margaret Buckingham; Simon J Conway; Marianne Gervais; Frédéric Relaix
Journal:  Cell Stem Cell       Date:  2019-04-18       Impact factor: 24.633

7.  Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs.

Authors:  Line Manceau; Julien Richard Albert; Pier-Luigi Lollini; Maxim V C Greenberg; Pascale Gilardi-Hebenstreit; Vanessa Ribes
Journal:  PLoS Genet       Date:  2022-05-23       Impact factor: 6.020

Review 8.  Novel pathways and molecular targets for the treatment of sarcoma.

Authors:  Ashley E Frith; Angela C Hirbe; Brian A Van Tine
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

9.  A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy.

Authors:  Johanna Pruller; Isabella Hofer; Massimo Ganassi; Philipp Heher; Michelle T Ma; Peter S Zammit
Journal:  Cancer Gene Ther       Date:  2020-09-25       Impact factor: 5.987

10.  Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis.

Authors:  Amy D Marshall; Gerard C Grosveld
Journal:  Skelet Muscle       Date:  2012-12-03       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.